Tetracycline

Combined use of acitretin and tetracyclines is contraindicated because both can cause increased intracranial pressure.

Concomitant use should be avoided due to association with intracranial hypertension (pseudotumor cerebri).

Systemic retinoid use with tetracyclines associated with benign intracranial hypertension cases. Avoid coadministration of SOHONOS with tetracycline derivatives.

Can cause intracranial hypertension; concomitant use with tretinoin may increase this risk. Avoid concomitant use.

Phototoxic agents that may cause severe phototoxic skin reaction (severe sunburn). Avoid for 24 hours before and after ALA administration.

May prolong neuromuscular blockade action of cisatracurium besylate. Use peripheral nerve stimulator and monitor clinical signs.

Absorption of tetracycline is significantly decreased when given simultaneously with colestipol hydrochloride.

Increased cardiotoxicity may result from combined effect with cyclophosphamide.

Anthracyclines potentiate cyclophosphamide's cardiotoxicity when used concomitantly or sequentially.

Drug Interactions Because tetracyclines have shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillins, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.

Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillins, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.

Tetracycline may antagonize the bactericidal effect of dicloxacillin; concurrent use should be avoided.

Increases digoxin serum concentration by 100%. Requires monitoring and dose reduction of 30-50%.

Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.

Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.

Patients receiving anthracyclines less than 4 months after stopping MARGENZA may be at increased risk of cardiac dysfunction. Avoid anthracycline-based therapy for up to 4 months after stopping MARGENZA.

Highly protein-bound drug that may increase methotrexate plasma concentrations, increasing risk of severe adverse reactions and potentially reducing clinical effectiveness.

Highly protein-bound tetracyclines may increase methotrexate plasma concentrations, increasing risk of severe adverse reactions.

( 7.2 ) 7.1 Anticoagulants Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 7.2 Penicillin Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin.

Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.

Tetracycline may antagonize the bactericidal effect of nafcillin; concurrent use should be avoided.

Tetracycline may antagonize the bactericidal effect of oxacillin; concurrent use should be avoided.

Tetracycline may antagonize the bactericidal effect of oxacillin; concurrent use should be avoided.

Tetracycline may antagonize the bactericidal effect of penicillin; concurrent use should be avoided.

Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUFLAVE to avoid chelation with magnesium.

Parenteral administration may intensify or produce neuromuscular block and paralysis when used with pyridostigmine.

Concomitant use is not recommended due to risk of serotonin syndrome and hypertensive crisis.

Concomitant use of rasagiline with tetracyclic antidepressants is not recommended.

May enhance neuromuscular blocking action of rocuronium, prolonging neuromuscular block.

May enhance neuromuscular blocking action of rocuronium bromide, causing prolongation of neuromuscular block.

Administer tetracycline and fluoroquinolone antibiotics [see Drug Interactions (7.3) ] , iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.

Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to avoid chelation with magnesium.

Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUTAB to avoid chelation with magnesium.

Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of SUPREP Bowel Prep Kit to avoid chelation with magnesium.

Drug Interactions Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline in conjunction with penicillin or other bactericidal antibacterials. Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and preparations containing iron, zinc, or sodium bicarbonate.

Patients receiving anthracyclines after stopping trastuzumab may be at increased risk of cardiac dysfunction due to trastuzumab's long washout period. Avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab if possible.

Patients receiving anthracyclines after stopping HERCEPTIN HYLECTA may have increased risk of cardiac dysfunction due to long washout period. Avoid anthracycline-based therapy for up to 7 months after stopping; if used, closely monitor cardiac function.

Patients receiving anthracyclines after stopping trastuzumab may have increased risk of cardiac dysfunction due to trastuzumab's long washout period. Avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab; if used, closely monitor cardiac function.

Patients receiving anthracyclines after stopping trastuzumab may have increased risk of cardiac dysfunction due to trastuzumab's long washout period. Avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab; if used, closely monitor cardiac function.

Patients receiving anthracyclines after stopping trastuzumab may have increased risk of cardiac dysfunction due to trastuzumab's long washout period. Avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab; if used, closely monitor cardiac function.

Tetracyclines may intensify or produce neuromuscular block on their own and can cause unexpected prolongation of vecuronium-induced neuromuscular blockade.

Tetracyclines may interact with iron (ferrous fumarate), potentially affecting tetracycline absorption and efficacy.

Tetracyclines may interfere with bactericidal effects of amoxicillin, though clinical significance is not well documented.

May interfere with the bactericidal effect of ampicillin.

( 7.1 ) Concomitant administration of tetracycline reduces atovaquone concentrations; use caution when coadministering. Monitor patients for potential loss of efficacy of atovaquone if coadministration of tetracycline is necessary. 7.2 Tetracycline Concomitant administration of tetracycline and atovaquone oral suspension has been associated with a reduction in plasma concentrations of atovaquone [see Clinical Pharmacology ( 12.3 )].

Tetracycline reduces plasma concentrations of atovaquone. Parasitemia should be closely monitored.

( 7.1 ) Concomitant administration of tetracycline reduces atovaquone concentrations; use caution when coadministering. Monitor patients for potential loss of efficacy of atovaquone if coadministration of tetracycline is necessary. 7.2 Tetracycline Concomitant administration of tetracycline and atovaquone oral suspension has been associated with a reduction in plasma concentrations of atovaquone [see Clinical Pharmacology ( 12.3 )] .

Calcium acetate may decrease the bioavailability of tetracyclines. Administer tetracycline one hour before or three hours after calcium acetate.

Calcium acetate may decrease the bioavailability of tetracyclines. Administer tetracycline one hour before or three hours after calcium acetate capsules.

Cholestyramine may delay or reduce the absorption of tetracycline.

Cholestyramine may delay or reduce the absorption of tetracycline.

Cholestyramine may delay or reduce absorption of tetracycline.

Possible association with reduced efficacy and breakthrough bleeding, though less marked than with rifampin.

Possible association with reduced contraceptive efficacy, though less marked than rifampin.

Folic acid may interfere with the absorption and effectiveness of antibiotic tetracycline.

May increase glucose-lowering effect of glimepiride, increasing susceptibility to and/or intensity of hypoglycemia.

May partially counteract the anticoagulant action of heparin. Careful monitoring recommended.

Tetracycline's antianabolic activity may reduce the potential effects of amino acids infused with dextrose as part of parenteral feeding regimen.

Lanthanum carbonate may reduce bioavailability of tetracyclines. Do not administer within 2 hours of lanthanum carbonate dosing.

Possible association with reduced efficacy and breakthrough bleeding, though less marked than with rifampin.

Metoclopramide may increase the rate and/or extent of absorption of tetracycline from the small bowel.

Metoclopramide may increase the rate and/or extent of absorption of tetracycline from the small bowel.

Tetracyclines interact with iron; prescriber should be aware of potential effects on drug efficacy.

Tetracycline may antagonize the bactericidal effect of nafcillin; concurrent use should be avoided.

Pregnancy has been reported with concurrent use of tetracycline and oral contraceptives, though clinical studies have not demonstrated consistent effects on synthetic steroid concentrations.

Pregnancy while taking combined oral contraceptives has been reported with tetracycline, though clinical studies have not demonstrated consistent effects on synthetic steroid concentrations.

Possibly associated with reduced contraceptive efficacy and menstrual irregularities.

Bacteriostatic antibacterial may antagonize the bactericidal effect of penicillin. Concurrent use should be avoided.

Tetracycline may antagonize the bactericidal effect of penicillin; concurrent use should be avoided.

Bacteriostatic antibiotic may antagonize the bactericidal effect of penicillin. Concurrent use should be avoided.

May antagonize the bactericidal effect of penicillin. Concurrent use should be avoided, though clinical significance is not well-documented.

Concomitant use may increase the risk of photosensitivity reaction. Avoid concomitant use with other photosensitizing agents.

Quinapril reduces tetracycline absorption by approximately 28% to 37%, possibly due to high magnesium content in quinapril tablets.

Simultaneous administration reduces tetracycline absorption by approximately 28-37%, possibly due to high magnesium content in quinapril tablets.

Simultaneous administration reduces tetracycline absorption by 28-37%, possibly due to high magnesium content in quinapril tablets.

May be concomitantly administered with quinine. Patients should be monitored closely for adverse reactions associated with quinine.

May be concomitantly administered with quinine sulfate capsules. Patients should be monitored closely for adverse reactions associated with quinine.

Sucralfate reduces the bioavailability of tetracycline. Separate dosing administration is recommended.

Other photosensitizing agents that could increase the potential for skin photosensitivity reactions.

albuterol, systemic and inhaled amoxicillin ampicillin, with or without sulbactam atenolol azithromycin caffeine, dietary ingestion cefaclor co-trimoxazole (trimethoprim and sulfamethoxazole) diltiazem dirithromycin enflurane famotidine felodipine finasteride hydrocortisone isoflurane isoniazid isradipine influenza vaccine ketoconazole lomefloxacin mebendazole medroxyprogesterone methylprednisolone metronidazole metoprolol nadolol nifedipine nizatidine norfloxacin ofloxacin omeprazole prednisone, prednisolone ranitidine rifabutin roxithromycin sorbitol (purgative doses do not inhibit theophylline absorption) sucralfate terbutaline, systemic terfenadine tetracycline tocainide The Effect of Other Drugs on Theophylline Serum Concentration Measurements: Most serum theophylline assays in clinical use are immunoassays which are specific for theophylline.

May interfere with the bactericidal effects of penicillin in vitro; clinical significance is not well documented.

( 5.14 , 7.5 ) Antacids, Multivitamins or Dairy Products: Decreased absorption of Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules; do not take concomitantly. ( 7.8 , 7.9 ) 7.1 Disulfiram Psychotic reactions have been reported in alcoholic patients who are using metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride and disulfiram concurrently. Bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride should not be given to patients who have taken disulfiram within the last two weeks [see Contraindications ( 4.1 )] .

(see Inactive ingredients ) For Tetracycline or Quinolones co-administration with Acunol, see Dosage and Administration

Drug Interactions In a PK drug interaction study, oral administration of tetracycline HCl, 500 mg four times daily for 3 days prior to and 7 days during wear of norelgestromin and ethinyl estradiol transdermal system did not significantly affect the PK of NGMN or EE.

Drugs that have been documented not to interact with theophylline or drugs that produce no clinically significant interaction with theophylline.* albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without methylprednisolone sulbactam metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride Sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin * Refer to PRECAUTIONS, Drug Interactions for information regarding table.

albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone atenolol metronidazole azithromycin metoprolol caffeine, dietary ingestion nadolol cefaclor nifedipine co-trimoxazole (trimethoprim and sulfamethoxazole) nizatidine diltiazem norfloxacin dirithromycin ofloxacin enflurane omeprazole famotidine prednisone, prednisolone felodipine ranitidine finasteride rifabutin hydrocortisone roxithromycin isoflurane Sorbitol (purgative doses do not inhibit theophylline absorption) isoniazid sucralfate isradipine terbutaline, systemic influenza vaccine terfenadine ketoconazole tetracycline lomefloxacin tocainide